Sionna Therapeutics, Inc./$SION
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Sionna Therapeutics, Inc.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
- Ticker
- $SION
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 59
- Headquarters
- Waltham, United States
- Website
- www.sionnatx.com
SION Metrics
BasicAdvanced
$148M
-
-$2.17
-
-
Price and volume
Market cap
$148M
52-week high
$54.97
52-week low
$3.19
Average daily volume
976K
Financial strength
Current ratio
20.045
Quick ratio
19.573
Long term debt to equity
0.025
Total debt to equity
0.03
Profitability
EBITDA (TTM)
-108.836
Management effectiveness
Return on assets (TTM)
-21.54%
Return on equity (TTM)
-32.34%
Valuation
Price to book
0.56
Price to tangible book (TTM)
0.56
Price to free cash flow (TTM)
-1.933
Free cash flow yield (TTM)
-51.73%
Free cash flow per share (TTM)
-1.697
Growth
Earnings per share change (TTM)
-42.82%
What the Analysts think about SION
Analyst ratings (Buy, Hold, Sell) for Sionna Therapeutics, Inc. stock.
Analyst projections of the future price of Sionna Therapeutics, Inc. stock.
SION Financial Performance
Revenues and expenses
SION Earnings Performance
Company profitability
Upcoming events
No upcoming events
SION News
AllArticlesVideos
SION INVESTIGATION ALERT: Investigation Launched into Sionna Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
Newsfile Corp3 months ago
Investigation Launched into Sionna Therapeutics, Inc. (SION), Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
Business Wire3 months ago
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Business Wire3 months ago
Funds containing SION
Fund name | Fund size | $SION weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.01% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.01% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.00% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.00% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.